ABSTRACT
The relatively benign and self-limited illnesses associated with most of the viral respiratory pathogens present both unique opportunities and formidable challenges for the design of clinical trials. In contrast to most other pathogens, these organisms lend themselves to experimentally induced infections for studies of both pathogenesis and treatment. Clinical trials conducted in both the experimental infection model and in natural infections have contributed to our understanding of these illnesses and the evaluation of effective treatments.
